Skip to main content

Table 2 Median maternal angiogenic biomarker levels for the Nicotine exposure study group (n = 2278)

From: The effect of nicotine-containing products and fetal sex on placenta-associated circulating midpregnancy biomarkers

Characteristics

N

%

sFlt-1, pg/mL

PlGF, pg/mL

sFlt-1/PlGF ratio

Median

IQR

Median

IQR

Median

IQR

Total biomarker study group

2603

 

1258.0

938.0–1754.0

192.0

142.0–260.0

6.8

4.5–9.7

Nicotine exposure study group

2278

 

1257.0

937.8–1753.0

193.0

143.0–261.0

6.7

4.4–9.7

Snus

2278

       

Never

1762

77.3

1245.0

935.0–1729.3

195.0

144.0–263.0

6.6

4.4–9.6

Stopped before pregnancy

343

15.1

1334.0

971.0–1905.0

189.0

141.0–253.0

7.1

4.8–10.7

Stopped when recognizing pregnancy

160

7.0

1252.5

903.0–1752.8

183.5

143.3–265.0

7.1

4.6–9.4

Current

13

0.6

996.0

729.5–1392.5

166.0

93.5–204.5

6.6

5.2–8.9

Smoking

2217*

       

Never

1762

79.4

1264.5

946.8–1754.3

192.0

143.0–261.3

6.8

4.5–9.8

Stopped before pregnancy

343

15.5

1238.5

915.3–1761.8

194.0

142.0–261.0

6.7

4.5–9.3

Stopped when recognizing pregnancy

97

4.4

1216.0

869.0–1687.0

189.0

142.0–247.5

6.7

4.6–9.9

Current

15

0.7

1146.0

820.0–1928.0

240.0

176.0–303.0

4.3

2.8–10.2

  1. IQR, interquartile range; n, number; P, p-value; pg/mL, picograms per milliliter; PlGF, Placental Growth Factor; sFlt-1, Soluble Fms-like tyrosine kinase receptor 1; *, missing data